





Q4 FY2017 Year-end and Quarterly Results - Investor presentation 1 June 2017





THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES IN THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION. IT IS PROVIDED AS INFORMATION ONLY

This presentation is furnished only for the use of the intended recipient, and may not be relied upon for the purposes of entering into any transaction. By attending this presentation, you agree to be bound by these restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Certain information herein (including market data and statistical information) has been obtained from various sources. We do not represent that it is complete or accurate. All projections, valuations and statistical analyses are provided to assist the recipient in the evaluation of the matters described herein. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent that they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

This presentation may include forward-looking statements that reflect our intentions, beliefs or current expectations. Forward-looking statements involve all matters that are not historical by using the words "may", "will", "would", "expect", "intend", "estimate", "anticipate", "believe", and similar expressions or their negatives. Such statements are made on the basis of assumptions and expectations that we currently believe are reasonable, but could prove to be wrong.

This presentation does not constitute an offer or an agreement, or a solicitation of an offer or an agreement, to enter into any transaction (including for the provision of any services) and does not constitute an offer or invitation to subscribe for or purchase any securities, and nothing contained herein shall form the basis of any contract or commitment whatsoever. Any decision to purchase securities in the context of a proposed offering, if any, should be made solely on the basis of information contained in the offering memorandum published in relation to such an offering.

The information contained herein does not constitute investment, legal, accounting, regulatory, taxation or other advice and the information does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs. You are solely responsible for forming your own opinions and conclusions on such matters and the market and for making your own independent assessment of the information herein. You are solely responsible for seeking independent professional advice in relation to the information and any action taken on the basis of the information. Investors and prospective investors in the securities of any issuer mentioned herein are required to make their own independent investigation and appraisal of the business and financial condition of such issuer and the nature of the securities.

This presentation includes certain financial data that are "non-IFRS financial measures". These non-IFRS financial measures do not have a standardised meaning prescribed by International Financial Reporting Standards or UK Accounting Standards and therefore may not be directly comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with International Financial Reporting Standards or UK Accounting Standards. Although we believe these non-IFRS financial measures provide useful information to users in measuring the financial performance and condition, of the business, you are cautioned not to place undue reliance on any non-IFRS financial measures included in this presentation. This presentation contains certain data and forward looking statements regarding the UK economy, the markets in which we operate and its position in the industry that were obtained from publicly available information, independent industry publications and other third party data. We have not independently verified such data and forward looking statements and cannot guarantee their accuracy or completeness.

## **Agenda**



- Introducing new IDH leadership
- Business overview
- FY2017 performance & business update
  - Patient services (mydentist) developments
  - Practice services (**Dental Directory**) developments
- FY2017 financial review
- Outlook
- Summary

## **Introducing new IDH leadership**





#### **Tom Riall** – Chief Executive

- Joined Integrated Dental Holdings (IDH) as Group Chief Executive Officer ("CEO") in May 2017
- Previously CEO of the Priory Group (also bond financed) from April 2013 to December 2016.
   Following successful sale to Acadia Healthcare Services exited at year-end
- Before Priory, 9 years with Serco, latterly as CEO of their Global Services division
- Currently undertaking an in-depth review of IDH business performance and will present next steps at the half-year investor presentation in November 2017







- IDH is Europe's largest vertically integrated dental services business
- We believe in high clinical standards, the best possible patient care and offering a comprehensive choice of treatment (NHS or private pay) through our extensive network of practices across the UK
- Within the IDH group there are two principal businesses:
  - mydentist (c.80% of group sales)
  - **Dental Directory** (including a number of sub-brands)



- Patient services, branded as mydentist is the UK's #1 network of dental practices
  - 674 practices nationwide
  - 1.5x the size of the next largest group
  - Serves over 5 million patients (NHS and private pay)
- Practice services, branded as **Dental Directory** is a leading provider of dental supplies and laboratory services
  - Includes a number of sub-brands; dbg, Mi-Tec, TAG, PDS, Dolby Medical
  - Facilities in Witham (Essex), Blackpool, Bradford and Stirling
- Together these two businesses (mydentist and Dental Directory) make up IDH Group



- IDH clear market leader with scale and extensive geographic reach.
   It is both a trusted partner to the NHS and a growing private pay business
- Core is stable and cash generative
- Focus is on high quality patient care and offering choice. All 674 practices in mydentist are 100% CQC compliant
- New, fresh brand in "mydentist" and well invested estate
- Solid platform for the future to increase % completion of UDAs and further grow private, but a number of issues to address
- New Board and new leadership in place to take the group forward



FY2017 performance & business update



## **FY2017 financial performance**





#### Group

- Revenue growth 3.5% YoY to £585.8m
- EBITDA down 14.2% YoY to £68.8m
- Normalised cash conversion remains strong at 91.9%



#### mydentist

- Private revenue LFL growth of 7.0%
- Overall LFL NHS revenues have reduced offset by private revenue growth
- Gross margin impacted through increased resourcing costs



#### **Dental Directory**

- Revenue growth 14.8% YoY to £135.0m (before intergroup eliminations)
- Gross margins recovering post-FX volatility resulting from Brexit



- 674 practices with 602 NHS contracts representing c.15% of NHS dental services in England & Wales
- "Evergreen" contracts enhance defensive qualities of the business and ongoing revenue streams
- FY2017 UDA delivery rate @ 90.4% (FY2016 92.4%)\*
- Before contract handbacks delivery rate equates to 88.0% of UDAs/overall contract value (FY2016 – 92.4%)
- Continuing to increase share of £3.4bn private market (currently only c.2%)
- Continued progress private revenue LFL growth:
  - YoY LFL 7.0%;
  - 2 year LFL 19.8%

<sup>\*</sup> Post in-year temporary and permanent handbacks.



### NHS market continues to be challenging

- NHS revenue of £385.1m down £1.3m (0.3%) due to decline in UDA delivery of 4.4%, offset by the contract price uplift of 0.7% and annualisation of acquisitions
- Following the impact of NHS scrutiny through FY2015 and FY2016, fall is due to a combination of:
  - Reduced number of UDAs per dentist and therefore the requirement to increase the overall number of dentists (this is underway)
  - Dentist productivity (increased NHS appointment times)
  - The influence of private revenue growth with patient choice
- Plans in place to increase UDA delivery by increasing the number of dentists, holding dentists to deliver on their committed UDAs and increasing productivity where possible



#### **Dedicated recruitment drive**

- Recruitment: important to recovery in UDA delivery
  - YoY net 154 extra clinicians in place at March 2017
  - Recruitment from contract acceptance can take up to 6 months for UK GDC registered dentists with notice periods and regulatory registrations and 12 months for EU and ORE\* candidates
- Different recruitment channels being developed further
  - EU recruitment in parallel with UK sourcing
  - Developing therapist model to support overseas recruitment
  - Continual focus on developing pipeline
  - Local attraction/ambassador initiatives around groups of practices
  - Targeted programme for passive candidates, including call centre
  - Encouraging more of our own dentists to become "mentors" to UK registered dentists coming out of dental colleges and/or other overseas dentists looking to practice in the UK
- Clinician turnover remains at low levels, c.10% for FY2017



### Focus on productivity

- Productivity:
  - R4+ practice management system upgrade rolled out,
  - Smart diary and patient note templates all now in place
  - Have committed to 100% rollout of digital x-rays over next 18 months
- Much of the above (improved resourcing pipeline, improvements to productivity) will take some time to impact performance

 Undelivered UDAs result in foregone revenue in a period, but not necessarily a loss of potential revenue for future periods



### **Continued YoY LFL growth in private revenues**

- Private revenue of £95.8m up £9.5m (11.0%) driven primarily by LFL growth
- Encouraging growth seen in all segments:

#### Fee per item ("FPI"):

- Consistent minimum pricing model in place across all practices
- "Smilechecker" & free assessment days have all supported FPI growth
- Denture Excellence, 34% LFL revenue growth, FY2017 £4.1m revenue
- Growing number of specialists and internal referrals across our practice network

#### Hygiene:

- 11.0% LFL revenue growth, FY2017 £15.3m revenue
- 505 hygienists contracted across 562 practices
- Growth opportunities both in number of increasing hygienists & sessions
- Underpinned by hygiene plan operating successfully across 239 practices

## **FY2017 highlights – Dental Directory**



# Development of dental services (supplies, wholesale, laboratories) making good progress

- Total revenue including intragroup to mydentist up 14.8% (£17.4m) YoY
- Growth also driven by acquired businesses



- Sales up 11.0% with encouraging volume growth in H2
- Both England & Scotland Health authority contracts performing well
- 5.7% sales growth in own label product lines providing future sales & margin opportunities
- Disciplined category and pricing structures in place backed by marketing activity programmes, including "Pink Thursdays"
- Web based sales increased by 17% to 65% of orders placed online.
- CRM platform allows visibility of all customer activity to tailor offers
- FX volatility post-Brexit vote mitigated through supplier support and selective price increases, gross margin % returning to normalised/long term levels

## **FY2017 highlights – Dental Directory**







- Rollout substantially completed Q1 FY2018
- Productivity and job volumes already increasing



- Med-FX is a single-source supplier for all Facial Aesthetics and Skin Rejuvenation product needs.
- FY2017: 27% LFL growth YoY to £12.3m.
- e-script introduction improved supply chain and customer efficiencies and further growth opportunities to individual practitioners, including mydentist clinicians



- Dolby Medical is Scotland's leading supplier of dental equipment and services to both NHS and private practitioners
- FY2017 trading ahead of management expectations
- Already providing platform to support & build on NHS Scotland and DenPro consumables contracts with other services

## **FY2017 highlights – Dental Directory**





- State of the art dental laboratory provides dentists with assistance in all aspects of Crown and Bridge, Dentures and implant work
- Restructuring of operational model and cost base carried out over FY2017
- Key customer contracts secured plus new wins
- Supporting the successful mydentist Denture Excellence programme with volume growth potential through FY2018
- Winner of The Dental Awards "Dental Laboratory of the Year 2017"







## **FY2017 Financial highlights**



- Revenue up 3.5% to £585.8m
- LFL mydentist private revenue up 7.0%
- Private revenue now 16.4% of total revenue (FY2016: 15.3%)
  - NHS revenue 65.7% of total (FY2016: 68.3%)
  - Dental Directory revenue 17.9% of total (FY2016: 16.4%)
- EBITDA down 14.2% on FY2016 to £68.8m
- Estimated pro-forma LTM EBITDA of £70.3m following six practice acquisitions
- Normalised cash conversion after maintenance capital expenditure remains stable at 91.9% (FY2016: 97.1%)
- Refinancing completed in August 2016 extending maturity of debt facilities to 2022/23

# Financial results for FY2017 Income statement




	2017 £m	% of revenue	2016 £m	% of revenue	% change
Revenue	585.8		565.9		3.5%
Gross profit	261.0	44.6%	258.4	45.7%	1.0%
Overheads*	(194.2)	33.1%	(180.1)	31.8%	(7.8%)
Other operating income	2.0	0.3%	1.9	0.3%	2.4%
EBITDA	68.8	11.7%	80.2	14.2 %	(14.2%)

<sup>\*</sup> Administrative expenses plus distribution costs before depreciation, amortisation, impairment and other non-underlying items

## Financial results for FY2017


Group revenue bridge





# **Financial results for FY2017**Group EBITDA bridge





## Financial results for FY2017

### Acquisitions & Disposals



- Total of 674 practices at 31 March 2017 (672 at 31 March 2016)
- Six practices acquired this year, with two closures and two practices merged into existing practices
- Strategy to limit acquisition activity for mydentist in FY2017 and FY2018 due to:
  - Continued high market valuations of practices
  - Group leverage
  - Focus on improving UDA delivery in existing practices
- Portfolio review underway
- Anticipated small number of practice disposals or closures
  - Three to date with two completed in FY2017
- Acquisitions of bolt-on companies to Dental Directory will continue dependent on the opportunities available and price

# Financial results for FY2017 Cash flow statement



£m	2017	2016
Cash generated from operations	72.9	80.0
Capital expenditure	(19.7)	(24.2)
Corporation tax	-	0.5
Cash flow before acquisitions and debt service	53.2	56.3
Interest	(38.5)	(35.2)
Cash flow before acquisitions and financing	14.7	21.1
Acquisitions*	(10.4)	(43.8)
Debt issue costs	(11.1)	-
Financing	4.5	8.5
Net cash flow	(2.3)	(14.2)
Opening cash	14.9	29.1
Closing cash	12.6	14.9
Net debt	527.6	516.9

<sup>\*</sup>Excluding fees

SSRCF remains undrawn - £100m (£98.2m available after Letter of Credit)

# Financial results for FY2017 Cash conversion



£m	2017	2016
Operating cash flow	72.9	80.0
Exceptionals	6.7	15.0
Acquisition fees	0.7	1.9
Working capital adjustments	(0.1)	0.2
Adjusted operating cash flow	80.2	97.1
Maintenance capital expenditure	(17.8)	(22.2)
Adjustments	0.9	3.0
Adjusted cash flow	63.3	77.9
EBITDA	68.8	80.2
Adjusted cash conversion %	91.9%	97.1%

# Financial results for Q4 FY2017 Income statement



	Q4 2017 £m	% of revenue	Q4 2016 £m	% of revenue	% change
Revenue	150.9		146.7		2.9%
Gross profit	66.1	43.8%	66.7	45.4%	(0.9%)
Overheads*	(49.4)	32.7%	(46.4)	31.6%	(6.5%)
Other operating income	0.4	0.3%	0.5	0.3%	(18.0%)
EBITDA	17.1	11.3%	20.8	14.2 %	(17.9%)

<sup>\*</sup> Administrative expenses plus distribution costs before depreciation, amortisation, impairment and other non-underlying items

# Financial results for Q4 FY2017 Cash flow statement



£m	Q4 2017	Q4 2016
Cash generated from operations	22.2	23.7
Capital expenditure	(3.6)	(6.5)
Corporation tax	-	-
Cash flow before acquisitions and debt service	18.6	17.2
Interest	(15.2)	(13.2)
Cash flow before acquisitions and financing	3.4	4.0
Acquisitions*	(0.7)	(7.7)
Debt issue costs	-	-
Financing	-	-
Net cash flow	2.7	(3.7)
Opening cash	9.9	18.6
Closing cash	12.6	14.9
Not dele	F.2.7. C	F1C 0
Net debt	527.6	516.9

<sup>\*</sup>Excluding fees



# Outlook

# Summary



- FY2017 a challenging year for both mydentist and Dental Directory
- Decline in UDA% completion must be corrected; pick up in resourcing and productivity should impact H2 FY2018
- Solid platform now in place to deliver longer term growth
- Private revenue growth in mydentist is encouraging and continues
- Dental Directory margins have recovered; acquisitions performing well and range of service offerings continues to expand
- Cash generative at operating levels
- New leadership in place



### **Contact details:**

Further questions can be addressed to:

- Email: investorrelations@mydentist.co.uk

- Telephone: 01204 799651

Investor information is available from our dedicated investor website:

www.mydentist.co.uk/about-us/investors

